Compare US Global Jets ETF (JETS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Global Jets ETF vs BIO-TECHNE Corp — how do they compare? US Global Jets ETF trades at $30.47, while BIO-TECHNE Corp trades at $71.7 (market cap $11.16B). The key difference: BIO-TECHNE Corp pays a 0.45% dividend while US Global Jets ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, US Global Jets ETF nearer its low. Which is the better fit depends on your goals.
| JETS | TECH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $33.34 | $72.12 |
52-Week Low | $23.12 | $43.31 |
Market Cap | — | $11.16B |
Enterprise Value | — | $11.24B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JETS trades at $30.58, up 0.39% with mixed technical signals showing a bullish overall trend but bearish moving averages and oscillators. The ETF faces headwinds from rising fuel costs as U.S. airlines spent $6.66 billion on jet fuel in May 2026 (U.S. Transportation Department, July 2026), though falling oil prices recently provided some relief. Technical indicators show RSI levels in oversold territory at 24.66 for the 12-day period, suggesting potential buying opportunity.
The outlook remains cautious as airline profits face pressure from fuel volatility and Middle East conflict impacts. While lower oil prices offer temporary relief, the sector's cyclical nature and competitive dynamics with defense-focused ETFs present ongoing challenges. Investment opportunity exists for those betting on travel recovery, but risks from fuel price shocks and operational disruptions require careful monitoring.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
